Brief: Spruce Biosciences Announces Positive Type B Meetings With U.S. FDA For Ta-Ert For The Treatment Of Sanfilippo Syndrome Type B
18/02/2026 12:26
Feb 18 (Reuters) - Spruce Biosciences Inc SPRB.O: SPRUCE BIOSCIENCES ANNOUNCES POSITIVE TYPE B MEETINGS WITH U.S. FDA FOR TA-ERT FOR THE TREATMENT OF SANFILIPPO SYNDROME TYPE B (MPS IIIB) SPRUCE BIOSCIENCES INC - TA-ERT BLA SUBMISSION ANTICIPATED IN Q4 Source text: ID:nBw76LgVSa Further company coverage: SPRB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium